Veracyte Inc
VCYT42.490USD
-0.280-0.65%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
3.36BMarket Cap
109.75P/E TTM
More Details of Veracyte Inc Company
Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and help patients to diagnose and treat cancer. The Veracyte Diagnostics Platform delivers cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and an evidence-generation engine, which drives durable reimbursement and guideline inclusion for its tests, along with new insights to support continued innovation and pipeline development. The Company offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna) and bladder cancer (Decipher Bladder). It has developed the noninvasive Percepta Nasal Swab test to help physicians accurately and quickly determine lung cancer risk. All of its tests are serviced through its own Clinical Laboratory Improvement Amendments (CLIA) certified laboratories in South San Francisco, California, San Diego, California and Austin, Texas.
Veracyte Inc Info
Ticker SymbolVCYT
Company nameVeracyte Inc
IPO dateOct 30, 2013
CEOStapley (Marc A)
Number of employees824
Security typeOrdinary Share
Fiscal year-endOct 30
Address6000 Shoreline Court, Suite 300
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94080
Phone16502436300
Websitehttps://www.veracyte.com/
Ticker SymbolVCYT
IPO dateOct 30, 2013
CEOStapley (Marc A)
Company Executives of Veracyte Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Marc A. Stapley
Mr. Marc A. Stapley
Chief Executive Officer, Director
Chief Executive Officer, Director
85.35K
-15.44%
Dr. Robert S. (Rob) Epstein, M.D.
Dr. Robert S. (Rob) Epstein, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
50.97K
-18.37%
Dr. Eliav Barr, M.D.
Dr. Eliav Barr, M.D.
Independent Director
Independent Director
32.81K
+39.68%
Ms. Muna Bhanji
Ms. Muna Bhanji
Independent Director
Independent Director
27.84K
+20.48%
Mr. Evan Jones
Mr. Evan Jones
Independent Director
Independent Director
17.89K
-44.43%
Mr. Jens Holstein
Mr. Jens Holstein
Independent Director
Independent Director
15.73K
-38.87%
Ms. Rebecca Chambers
Ms. Rebecca Chambers
Chief Financial Officer
Chief Financial Officer
4.31K
-79.45%
Mr. John Leite, Ph.D.
Mr. John Leite, Ph.D.
Global Chief Commercial Officer
Global Chief Commercial Officer
2.81K
-67.00%
Ms. Annie Mcguire
Ms. Annie Mcguire
Chief Human Resources Officer, General Counsel
Chief Human Resources Officer, General Counsel
2.24K
-49.11%
Ms. Karin Eastham, CPA
Ms. Karin Eastham, CPA
Independent Director
Independent Director
2.08K
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Marc A. Stapley
Mr. Marc A. Stapley
Chief Executive Officer, Director
Chief Executive Officer, Director
85.35K
-15.44%
Dr. Robert S. (Rob) Epstein, M.D.
Dr. Robert S. (Rob) Epstein, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
50.97K
-18.37%
Dr. Eliav Barr, M.D.
Dr. Eliav Barr, M.D.
Independent Director
Independent Director
32.81K
+39.68%
Ms. Muna Bhanji
Ms. Muna Bhanji
Independent Director
Independent Director
27.84K
+20.48%
Mr. Evan Jones
Mr. Evan Jones
Independent Director
Independent Director
17.89K
-44.43%
Mr. Jens Holstein
Mr. Jens Holstein
Independent Director
Independent Director
15.73K
-38.87%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2024
FY2023
FY2022
FY2021
FY2020
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
423.54M
95.01%
International
22.23M
4.99%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
14.32%
The Vanguard Group, Inc.
10.74%
Artisan Partners Limited Partnership
9.32%
Fidelity Management & Research Company LLC
7.27%
ARK Investment Management LLC
5.65%
Other
52.70%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
14.32%
The Vanguard Group, Inc.
10.74%
Artisan Partners Limited Partnership
9.32%
Fidelity Management & Research Company LLC
7.27%
ARK Investment Management LLC
5.65%
Other
52.70%
Shareholder Types
Shareholders
Proportion
Investment Advisor
70.40%
Investment Advisor/Hedge Fund
34.96%
Hedge Fund
4.61%
Research Firm
2.29%
Pension Fund
1.90%
Bank and Trust
0.51%
Individual Investor
0.42%
Sovereign Wealth Fund
0.06%
Family Office
0.05%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
616
87.37M
110.53%
-1.45M
2025Q2
598
84.22M
107.53%
-1.90M
2025Q1
612
85.86M
109.67%
-679.43K
2024Q4
593
81.64M
104.75%
-2.62M
2024Q3
567
81.88M
106.62%
-2.30M
2024Q2
533
81.65M
106.83%
-3.86M
2024Q1
532
81.30M
103.75%
+1.22M
2023Q4
524
76.49M
104.40%
-3.87M
2023Q3
520
77.05M
105.90%
-3.78M
2023Q2
516
77.28M
106.70%
-4.52M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
6.12M
7.78%
-81.10K
-1.31%
Jun 30, 2025
The Vanguard Group, Inc.
8.08M
10.27%
-163.29K
-1.98%
Jun 30, 2025
Artisan Partners Limited Partnership
6.32M
8.04%
+1.08M
+20.65%
Jun 30, 2025
Fidelity Management & Research Company LLC
6.93M
8.81%
+761.45K
+12.34%
Jun 30, 2025
ARK Investment Management LLC
3.80M
4.83%
+594.86K
+18.56%
Jun 30, 2025
State Street Investment Management (US)
3.17M
4.03%
+11.46K
+0.36%
Jun 30, 2025
Wellington Management Company, LLP
3.47M
4.42%
-379.35K
-9.85%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
3.02M
3.84%
+111.60K
+3.83%
Jun 30, 2025
ArrowMark Colorado Holdings, LLC
2.58M
3.28%
-647.85K
-20.08%
Jun 30, 2025
Geode Capital Management, L.L.C.
1.93M
2.46%
-3.46K
-0.18%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Invesco Biotechnology & Genome ETF
4.35%
ARK Genomic Revolution ETF
3.68%
First Trust NYSE Arca Biotechnology Index Fund
3.48%
Global X Genomics & Biotechnology ETF
3.13%
ROBO Global Healthcare Technology & Innovation ETF
2.19%
Invesco S&P SmallCap 600 Pure Growth ETF
1.97%
Invesco S&P SmallCap Health Care ETF
1.74%
Franklin Genomic Advancements ETF
1.45%
ROBO Global Artificial Intelligence ETF
1.43%
ARK Innovation ETF
1.24%
View more
Invesco Biotechnology & Genome ETF
Proportion4.35%
ARK Genomic Revolution ETF
Proportion3.68%
First Trust NYSE Arca Biotechnology Index Fund
Proportion3.48%
Global X Genomics & Biotechnology ETF
Proportion3.13%
ROBO Global Healthcare Technology & Innovation ETF
Proportion2.19%
Invesco S&P SmallCap 600 Pure Growth ETF
Proportion1.97%
Invesco S&P SmallCap Health Care ETF
Proportion1.74%
Franklin Genomic Advancements ETF
Proportion1.45%
ROBO Global Artificial Intelligence ETF
Proportion1.43%
ARK Innovation ETF
Proportion1.24%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Veracyte Inc?
The top five shareholders of Veracyte Inc are:
BlackRock Institutional Trust Company, N.A. holds 6.12M shares, accounting for 7.78% of the total shares.
The Vanguard Group, Inc. holds 8.08M shares, accounting for 10.27% of the total shares.
Artisan Partners Limited Partnership holds 6.32M shares, accounting for 8.04% of the total shares.
Fidelity Management & Research Company LLC holds 6.93M shares, accounting for 8.81% of the total shares.
ARK Investment Management LLC holds 3.80M shares, accounting for 4.83% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 6.12M shares, accounting for 7.78% of the total shares.
The Vanguard Group, Inc. holds 8.08M shares, accounting for 10.27% of the total shares.
Artisan Partners Limited Partnership holds 6.32M shares, accounting for 8.04% of the total shares.
Fidelity Management & Research Company LLC holds 6.93M shares, accounting for 8.81% of the total shares.
ARK Investment Management LLC holds 3.80M shares, accounting for 4.83% of the total shares.
What are the top three shareholder types of Veracyte Inc?
The top three shareholder types of Veracyte Inc are:
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
Artisan Partners Limited Partnership
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
Artisan Partners Limited Partnership
How many institutions hold shares of Veracyte Inc (VCYT)?
As of 2025Q3, 616 institutions hold shares of Veracyte Inc, with a combined market value of approximately 87.37M, accounting for 110.53% of the total shares. Compared to 2025Q2, institutional shareholding has increased by 2.99%.
What is the biggest source of revenue for Veracyte Inc?
In FY2024, the -- business generated the highest revenue for Veracyte Inc, amounting to -- and accounting for --% of total revenue.
